Aug 2026· Journal of Medicinal Chemistry· Vol 69 16, pp.
19951-19970
· 0 citations· 48 references
Medicine
TL;DR
This study designed and synthesized a series of nonquaternary ammonium analogs to investigate whether this structural motif could be removed without compromising KRAS rG4-related activity and identified Q29 as a promising lead for further development of KRAS translation inhibitors.
Abstract
KRAS mRNA G-quadruplexes (rG4s) in the 5'-untranslated region offer attractive targets for translational intervention in KRAS-driven cancers. We previously identified the quinoline-coumarin derivative 15a as a KRAS rG4 ligand that suppresses KRAS translation; however, its permanently charged quaternary ammonium center limits further optimization. Herein, we designed and synthesized a series of nonquaternary ammonium analogs to investigate whether this structural motif could be removed without compromising KRAS rG4-related activity. Q29 emerged as the most promising compound, showing high affinity for the KRAS rG4 and inhibiting KRAS translation. Q29 also exhibited potent antiproliferative activity across KRAS mutant cancer cells, improved cellular uptake and tolerability relative to 15a, and significant antitumor efficacy in a MIA PaCa-2 xenograft model. Collectively, our study establishes a viable strategy for optimizing KRAS rG4 ligands that retain activity despite removal of the permanent charge and identifies Q29 as a promising lead for further development of KRAS translation inhibitors.
Current KRASG12C inhibitors mainly target the inactive GDP-bound state, but clinical efficacy is limited, and resistance mechanisms have been identified. We disclose novel covalent inhibitors that selectively target the active GTP-bound KRASG12C. Starting from a high-throughput screen, we identified a keto-indolizine...
Juan del Pozo, Elisabeth T. Hennessy, Patrick Schoepf et al.· Journal of Medicinal Chemist...· 0 citations
KRAS, a frequently mutated oncogene, has been demonstrated to harbor multiple mutant variants. Although KRAS G12C inhibitors have been successfully approved for clinical use, their efficacy remains limited by acquired resistance and narrow patient eligibility. Here, we leveraged the proteolysis-targeting chimera (PROTA...
Shen-Xin Zeng, Yi-Qing Zhao, Yan-Qing Liu et al.· European journal of medicina...· 0 citations
Current evidence suggests that enhanced CDK4 selectivity and rational combination strategies may improve the therapeutic index in NSCLC and coumarin-based scaffolds are promising platforms for CDK4-targeted drug development.
N. M. Arulmozhi, Thiyagarajan Gopal· Current Pharmacology Reports· 0 citations
The results demonstrate that a conformational rigidification through a bridged scaffold, implemented while preserving membrane permeability, is a highly effective strategy for achieving isoform selectivity.
M. Kage, Hatsuo Kawada, Koji Takano et al.· Journal of the American Chem...· 0 citations
Overall, the collective evidence establishes coumarin as a highly adaptable scaffold for the development of next-generation antibacterial agents and highlights integrated structure-based design, dual-target inhibition, and comprehensive biological validation as key priorities for future medicinal chemistry research.
Combined computational and preliminary cell-based findings support compound 4i as a promising lead for further investigation of EGFR-targeted anticancer activity and biochemical EGFR kinase inhibition and target-engagement studies are required to determine the mechanism of action.
S. Badadhe, Vikas B. Gawali, C. Jangme et al.· Journal of the Iranian Chemi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.